Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Want to see AU:NEU full AI Analyst Report?
Top Page
Neuren Pharmaceuticals Limited
(Sydney:NEU)
Select Model
Select Model
Rating:59Neutral
Price Target:
AU$15.00
▲(20.10% Upside)
Action:Reiterated
Date:03/01/26
The score is primarily supported by strong recent profitability and a debt-free balance sheet, but is materially offset by a pronounced technical downtrend and a high P/E valuation. Revenue and cash flow volatility further reduce confidence in the stability of recent results.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and preserves flexibility to fund R&D, pursue licensing deals or pay milestones without needing immediate external financing. That structural conservatism supports multi-quarter resilience during revenue swings.
Negative Factors
Revenue volatility and recent decline
Large year-to-year swings in revenue undermine visibility for R&D pacing, partner negotiations and capital allocation. If royalties and milestones are lumpy, recurring revenue cannot be relied on quarter-to-quarter, increasing the likelihood of financing needs or delayed program timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and preserves flexibility to fund R&D, pursue licensing deals or pay milestones without needing immediate external financing. That structural conservatism supports multi-quarter resilience during revenue swings.
Read all positive factors
Neuren Pharmaceuticals Limited (NEU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.68B
Dividend YieldN/A
Average Volume (3M)305.98K
Price to Earnings (P/E)55.2
Beta (1Y)2.29
Revenue Growth-69.69%
EPS Growth-78.38%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding126,773,980
10 Day Avg. Volume278,541
30 Day Avg. Volume305,983
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)7.05
Price to Sales (P/S)36.92
P/FCF Ratio19.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$23.00Price Target Upside84.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$74.85M
Neuren Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Neuren Pharmaceuticals Limited, an Australian biopharmaceutical firm, is dedicated to developing innovative treatments for neurological conditions. Its leading drug candidate, trofinetide, is currently in advanced (Phase III) clinical trials for R...
How the Company Makes Money
Neuren makes money primarily through out-licensing and partnering its drug programs rather than directly marketing products itself. Its key revenue streams include: (1) Licensing and royalty revenue: Neuren licensed North American rights to trofin...
Neuren Pharmaceuticals Limited Earnings Call Summary
Earnings Call Date:Feb 29, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:Aug 25, 2026
Earnings Call Sentiment Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.Positive Updates
Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Negative Updates
Exchange Rate Impact
There was an $8.2 million expense due to exchange losses, partially offset by foreign exchange gains.
Read all updates
Q4-2023 Updates
Positive
Negative
Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Read all positive updates
Company Guidance
During Neuren's 2023 earnings call, CEO Jonathan Pilcher highlighted several key financial metrics. The company reported a profit of AUD 157 million, fueled by AUD 27 million in royalty income, a USD 59 million milestone payment from DAYBUE's first commercial sale in the U.S., and USD 146 million from an expanded deal with Acadia. Cash reserves increased from AUD 40 million to AUD 229 million without any capital raising. Neuren anticipates royalty income between AUD 61 million and AUD 70 million next year, based on a royalty rate that ranges from 10% to 12%. Additionally, Neuren is expecting USD 50 million in milestone payments as DAYBUE's sales exceed USD 250 million. Neuren's R&D expenses totaled AUD 27 million, with significant efforts directed towards four Phase II trials and preparations for Phase III. Acadia's DAYBUE guidance for 2024 forecasts USD 370 million to USD 420 million in sales, indicating substantial growth from 2023's USD 177 million.Neuren Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.63M | 213.24M | 231.93M | 14.55M | 3.20M |
| Gross Profit | 64.61M | 213.22M | 205.17M | 14.54M | 3.19M |
| EBITDA | 22.05M | 175.57M | 199.26M | -670.00K | -10.98M |
| Net Income | 30.44M | 142.04M | 157.08M | 184.00K | -7.79M |
Balance Sheet | |||||
| Total Assets | 342.86M | 409.71M | 247.97M | 43.27M | 40.06M |
| Cash, Cash Equivalents and Short-Term Investments | 296.12M | 222.24M | 228.54M | 40.18M | 36.78M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.41M | 45.80M | 42.76M | 1.68M | 803.00K |
| Stockholders Equity | 338.45M | 363.90M | 205.21M | 41.59M | 39.25M |
Cash Flow | |||||
| Free Cash Flow | 125.39M | -11.28M | 184.88M | 3.58M | -9.98M |
| Operating Cash Flow | 125.42M | -11.27M | 184.93M | 3.60M | -9.97M |
| Investing Cash Flow | -88.01M | 4.13M | -211.49M | -19.00K | -10.00K |
| Financing Cash Flow | -33.22M | -8.78M | 3.62M | -2.00K | 22.18M |
Neuren Pharmaceuticals Limited Technical Analysis
Negative
12.49
Price Trends
12.95
Negative
12.90
Negative
16.30
Negative
Market Momentum
-0.03
Positive
43.61
Neutral
39.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NEU, the sentiment is Negative. The current price of 12.49 is below the 20-day moving average (MA) of 13.58, below the 50-day MA of 12.95, and below the 200-day MA of 16.30, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.61 is Neutral, neither overbought nor oversold. The STOCH value of 39.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NEU.
Neuren Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.68B | 55.17 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.42B | -17.86 | -30.03% | ― | ― | 22.52% | |
43 Neutral | AU$131.80M | -6.23 | -134.14% | ― | ― | -64.71% | |
42 Neutral | AU$25.72M | -6.80 | -19.10% | ― | ― | -285.37% | |
39 Underperform | AU$19.15M | -6.35 | 44.23% | ― | -98.07% | ― | |
39 Underperform | AU$5.95M | -1.60 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:NEU
Neuren Pharmaceuticals Limited
12.74
0.48
3.92%
AU:ACW
Actinogen Medical
0.04
0.02
84.21%
AU:OPT
Opthea
0.01
-0.59
-97.67%
AU:ZLD
Zelira Therapeutics
0.50
0.08
19.05%
AU:PYC
PYC Therapeutics Limited
1.52
0.35
29.80%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.03
-31.11%
Neuren Pharmaceuticals Limited Corporate Events
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
Jun 1, 2026
Neuren Pharmaceuticals has notified the market of the issue of 360,000 new unquoted securities under its employee share scheme, dated May 27, 2026. The securities are subject to transfer restrictions and will not be quoted on the ASX until those r...
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
May 27, 2026
Shareholders of Neuren Pharmaceuticals have backed the re-election of director Joe Basile and approved the company’s auditor remuneration at its 2026 annual general meeting, with both resolutions passing by comfortable margins. Investors als...
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
May 27, 2026
Neuren reported strong financial performance for 2025, underpinned by DAYBUE royalties that drove a A$30 million profit, A$65 million in royalty income, and a cash position of A$296 million, giving the company substantial resources to fund its gro...
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
May 12, 2026
Neuren Pharmaceuticals has launched an Investor Hub and redesigned corporate website aimed at improving communication with shareholders, prospective investors and broader stakeholders as it advances its neurological drug portfolio. The new platfor...
Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
May 11, 2026
Neuren Pharmaceuticals has reported an update on its on-market share buy-back program for ordinary fully paid shares traded under ticker NEU on the ASX. The company disclosed that a total of 269,300 shares had been repurchased prior to the latest ...
Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026
May 7, 2026
Neuren Pharmaceuticals reported strong momentum in Q1 2026 via partner Acadia, with DAYBUE net sales rising 20% year-on-year to US$101 million and Neuren’s related royalties increasing 23% to US$10.4 million, while full-year DAYBUE sales gui...
Neuren Updates Market on Ongoing On-Market Share Buy-Back
May 6, 2026
Neuren Pharmaceuticals Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code NEU. The latest filing, dated 6 May 2026, confirms that this announcement is an amendment to...
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
Apr 24, 2026
Neuren Pharmaceuticals has issued an online meeting guide for shareholders and appointed proxies ahead of an upcoming virtual shareholder meeting. The guide details technical requirements, including supported browsers and necessary identification ...
Neuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
Apr 24, 2026
Neuren Pharmaceuticals has called its 2026 Annual Shareholders’ Meeting for 27 May in Melbourne, offering a hybrid format that allows investors to attend in person at the RACV City Club or participate online via a live webcast. Shareholders ...
Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards
Apr 24, 2026
Neuren Pharmaceuticals has lodged its Appendix 4G and confirmed that its corporate governance statement for the year ended 31 December 2025 is included in its latest annual report and current as of 31 March 2026. The filing, authorised by CFO and ...
Neuren details 2025 progress and governance in latest annual report
Apr 24, 2026
Neuren Pharmaceuticals has released its 2025 annual report, outlining progress in its pipeline of drug therapies aimed at neurodevelopmental disabilities and other serious neurological conditions with substantial unmet need. The report also detail...
Neuren Updates Market on Ongoing On‑Market Share Buy‑Back
Apr 20, 2026
Neuren Pharmaceuticals Limited has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest daily report states that a total of 172,700 shares had been repurc...
Neuren Pharmaceuticals Updates Market on Ongoing Share Buy-Back
Apr 19, 2026
Neuren Pharmaceuticals has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for ordinary fully paid shares under code NEU. The latest daily buy-back report, dated 20 April 2026, shows that the comp...
Neuren Updates Market on Progress of On-Market Share Buy-Back
Apr 16, 2026
Neuren Pharmaceuticals has provided an updated notification of its ongoing on-market share buy-back program for its ordinary fully paid shares on the ASX, coded NEU. The update records that a total of 140,700 shares had been repurchased prior to t...
Neuren Cancels Shares Following On-Market Buy-Back
Apr 10, 2026
Neuren Pharmaceuticals Limited has cancelled 140,700 ordinary fully paid shares following the execution of an on-market share buy-back completed on 31 March 2026. The reduction in issued capital may enhance earnings per share and capital efficienc...
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
Apr 8, 2026
Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has made DAYBUE STIX, a dye- and preservative-free powder formulation of Rett syndrome drug trofinetide, broadly available across the U.S. after a limited early 2026 launch. The portable...
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
Mar 26, 2026
Neuren Pharmaceuticals has notified the market of the cessation of 50,000 options with an exercise price of $19.63, which were due to expire on 19 September 2030. The options lapsed on 28 February 2026 because the conditions required for exercisin...
Neuren updates market on ongoing on‑market share buy‑back
Mar 23, 2026
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code NEU. It focuses on developing and commercialising pharmaceutical therapies, with its ordinary fully paid shares actively traded in the marke...
Neuren Updates Market on Ongoing On-Market Share Buy-Back
Mar 12, 2026
Neuren Pharmaceuticals Limited has provided an updated notice to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest daily notification, dated 13 March 2026, confirms that a total of 72,500...
Neuren director Joseph Basile lifts stake with on-market share purchase
Mar 5, 2026
Neuren Pharmaceuticals has disclosed a change in the shareholding of director Joseph Basile, who increased his direct interest in the company through an on-market trade. Basile acquired 12,300 ordinary shares on 5 March 2026 at $12.34 per share, l...
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
Mar 2, 2026
Neuren Pharmaceuticals said its partner Acadia Pharmaceuticals will seek a re-examination by the European Medicines Agency’s CHMP after the committee voted to refuse marketing authorisation for trofinetide to treat Rett syndrome in patients ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.